These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7702228)

  • 41. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.
    Lin WA; Tarn YH; Tang SL
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1483-93. PubMed ID: 17081165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon alfa-2b therapy in children with chronic hepatitis B.
    Sokal EM; Wirth S; Goyens P; Depreterre A; Cornu C
    Gut; 1993; 34(2 Suppl):S87-90. PubMed ID: 8314496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Chronic infection due to hepatitis B virus in patients less than 16 years of age: therapeutic approach by means of interferon alfa-2b].
    Vetencourt R; Oropeza F; de Armas J; Cordero I; de Silva M; Machado I; Vetencourt M; Mendoza J
    G E N; 1990; 44(4):353-60. PubMed ID: 2152277
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of treatments for chronic hepatitis C.
    Wong JB
    Am J Med; 1999 Dec; 107(6B):74S-78S. PubMed ID: 10653463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).
    Krogsgaard K; Bindslev N; Christensen E; Craxi A; Schlichting P; Schalm S; Carreno V; Trepo C; Gerken G; Thomas HC
    J Hepatol; 1994 Oct; 21(4):646-55. PubMed ID: 7814812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective trial of recombinant leucocyte interferon in chronic hepatitis B: a long-term follow-up study.
    Coppens JP; Cornu C; Lens E; Lamy M; Geubel AP
    J Hepatol; 1990; 11 Suppl 1():S126-8. PubMed ID: 2079569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
    Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up.
    Zavaglia C; Bottelli R; Bellati G; Asti L; Mondazzi L; Iamoni G; Zanetti A; Tanzi E; Fesce E; Gelosa F; Maggi G; Ideo G
    Ital J Gastroenterol; 1996; 28(6):324-31. PubMed ID: 8891847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland.
    Orlewska E
    Value Health; 2002; 5(5):405-21. PubMed ID: 12201858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
    Wong JB; Davis GL; McHutchison JG; Manns MP; Albrecht JK;
    Am J Gastroenterol; 2003 Nov; 98(11):2354-62. PubMed ID: 14638334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
    Niederau C; Heintges T; Lange S; Goldmann G; Niederau CM; Mohr L; Häussinger D
    N Engl J Med; 1996 May; 334(22):1422-7. PubMed ID: 8618580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.
    Perrillo RP; Schiff ER; Davis GL; Bodenheimer HC; Lindsay K; Payne J; Dienstag JL; O'Brien C; Tamburro C; Jacobson IM; Sampliner R; Feit D; Lefkowitch J; Kuhns M; Meschievitz C; Sanghvi B; Albrecht J; Gibas A;
    N Engl J Med; 1990 Aug; 323(5):295-301. PubMed ID: 2195346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP).
    Fattovich G; Giustina G; Realdi G; Corrocher R; Schalm SW
    Hepatology; 1997 Nov; 26(5):1338-42. PubMed ID: 9362381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of interferon alpha-2b following prednisone withdrawal in the treatment of chronic viral hepatitis B. A case-controlled, randomised study.
    Robson SC; Brice E; van Rensburg C; Kannemeyer J; Hift RJ; Kirsch RE
    S Afr Med J; 1992 Nov; 82(5):317-20. PubMed ID: 1448711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Chronic hepatitis B. Treatment in childhood with alpha-interferon].
    Wirth S; Sokal E; Schaefer E; Pohlenz J; Keller KM
    Monatsschr Kinderheilkd; 1992 Oct; 140(10):775-9. PubMed ID: 1435800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b.
    Gu J; Sun R; Shen S; Yu Z
    Pak J Pharm Sci; 2015 Jul; 28(4 Suppl):1493-7. PubMed ID: 26431662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
    Hayashi PH; Beames MP; Kuhns MC; Hoofnagle JH; Di Bisceglie AM
    Am J Gastroenterol; 1996 Nov; 91(11):2323-8. PubMed ID: 8931411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A multicenter, randomized, open-label study of the safety and effectiveness of pegylated interferon alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients].
    Zhao H; Si CW; Wei L; Wan MB; Ying YK; Hou JL; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):323-6. PubMed ID: 16732903
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of chronic hepatitis B with interferon alpha-2b].
    Baumgarten R; Müller R; Markus R; Hintsche-Kilger B; Fengler JD; Meisel H
    Gastroenterol J; 1990; 50(3):124-8. PubMed ID: 2288653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.